Study of EZN-2208 Pediatric Patients With Solid Tumors



Status:Archived
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:February 2010

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors


The goal of this clinical research study is to find the highest tolerable dose of EZN-2208
that can be given to pediatric patients with Relapsed or Refractory Solid Tumors. The safety
of the study drug and its effect on the disease will also be studied.


Pharmacokinetic (PK) testing of EZN-2208, will be perfomed for patients who volunteer. PK
testing measures the amount of a drug in the body at different time points.


We found this trial at
2
sites
Brigham & Women's Hospital Women's Health Center
850 Boylston Street
Chestnut Hill, Massachusetts 02467
1-800-BWH-9999
Brigham & Women's Hospital Women's Health Center At Brigham and Women
?
mi
from
Chestnut Hill, MA
Click here to add this to my saved trials
Lia Gore, MD
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials